State of Care
Asthma is considered the most common chronic illness among both children and adults. The U.S. Department of Health and Human Services declared asthma an epidemic 15 years ago and has been working tirelessly to reduce asthma rates and costs. However, rates of asthma have only increased and healthcare costs have skyrocketed. The failure to reduce asthma rates can be attributed to its difficulty to manage and the lack of inexpensive and reliable methods to manage asthma. Mismanagement has resulted in increased rates of severe and uncontrolled asthma responsible for 80% of the costs associated with asthma management.
Current National Institutes of Health (NIH) guidelines dictate asthma should be diagnosed early and treated aggressively before a case of mild asthma progresses to severe asthma with a much higher risk of asthma attacks and significantly higher treatment costs. Asthma cannot be cured, but it can be controlled to afford patients a life without restrictions. Despite a clear plan of action, compliance rates with NIH guidelines remain unsatisfactory, likely due to patients refusing to regularly perform the uncomfortable and sometimes complex methods currently prescribed for asthma monitoring.
Our biomarker technology will offer a valuable opportunity to learn more about each patient's unique asthma patterns. Frequent monitoring could potentially reveal previously unknown triggers and verify suspected triggers. Long term monitoring will reflect an individual patient's overall lung condition and track their response to treatment.
New standard of care
The future of healthcare can be summarized as follows:
"The use of internet-based therapies combined with novel technologies to assess disease severity will become more common in future healthcare... The implementation of internet-based management tools in real life would therefore increase patient safety and improve the communication between patients and caregivers.”